Provided by Tiger Trade Technology Pte. Ltd.

Spruce Biosciences, Inc.

63.40
+4.758.10%
Pre-market: 65.101.70+2.68%04:20 EDT
Volume:147.30K
Turnover:9.09M
Market Cap:182.21M
PE:-1.65
High:64.15
Open:58.82
Low:58.00
Close:58.65
52wk High:240.00
52wk Low:7.26
Shares:2.87M
Float Shares:2.29M
Volume Ratio:1.93
T/O Rate:6.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-38.4300
EPS(LYR):-50.8298
ROE:-105.98%
ROA:-40.03%
PB:2.18
PE(LYR):-1.25

Loading ...

Spruce Biosciences Initiated at Buy by Craig-Hallum

Dow Jones
·
Apr 28

Craig-Hallum bullish on Spruce Biosciences, initiates with a Buy

TIPRANKS
·
Apr 27

Top Midday Decliners

MT Newswires Live
·
Apr 22

BUZZ-U.S. STOCKS ON THE MOVE-Intel, Teradyne, MSCI

Reuters
·
Apr 21

Top Premarket Decliners

MT Newswires Live
·
Apr 21

BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Tractor Supply, RTX

Reuters
·
Apr 21

Spruce Biosciences Shares Down 15.9% Premarket After Co Announces Pricing of Equity Offering

THOMSON REUTERS
·
Apr 21

Spruce Biosciences, Inc - Prices Public Offering of 1,150,000 Shares at $50.00 per Share

THOMSON REUTERS
·
Apr 21

Spruce Biosciences down 13% at $60.50 after equity offering announcement

TIPRANKS
·
Apr 21

BUZZ-Spruce Biosciences falls after equity offering launch

Reuters
·
Apr 21

Spruce Biosciences announces common stock offering, no amount given

TIPRANKS
·
Apr 21

Spruce Biosciences launches public offering of common stock, pre-funded warrants

Reuters
·
Apr 21

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Apr 21

Spruce Biosciences announces annual shareholder meeting via webcast

Reuters
·
Apr 10

BRIEF-Spruce Biosciences On March 16, Entered Termination Agreement With Kaken Pharmaceutical - SEC Filing

Reuters
·
Mar 21

Spruce Biosciences Ends Kaken Collaboration, Refocuses Pipeline

TIPRANKS
·
Mar 21

Spruce Biosciences Inc - Collaboration Agreement With Kaken Pharmaceutical to Terminate Effective March 31, 2026 - SEC Filing

THOMSON REUTERS
·
Mar 21

Spruce Biosciences Inc - All Licenses & Rights Granted by Co to Kaken to Be Terminatde; No Unearned Milestone Payments or Royalties

THOMSON REUTERS
·
Mar 21

Spruce Biosciences FY2025 R&D expenses fell 57.97% to USD 19.5 million, net loss was USD 39 million

Reuters
·
Mar 21

Spruce Biosciences Is Maintained at Market Outperform by Citizens

Dow Jones
·
Mar 10